NCT01308619 - Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Rosacea

Interventions

DRUG

Doxycycline

doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning

OTHER

Placebo

Placebo, oral, one capsule daily in the morning

Trial Locations (10)

Skin Search of Rochester, Inc, Rochester

The Indiana Clinical Trials Center, Plainfield

Hudson Dermatology, Evansville

Michigan Center for Research Corp, Clinton Township

Burke Pharmaceutical Research, Hot Springs

Suzanne Bruce and Associates, PA, Houston

J & S Studies, Inc., College Station

Derm Research, Austin

Therapeutics Clinical Research, San Diego

Oregon Medical Research Center, PC, Portland